OBI Pharma Announces Phase 1/2 Study Initiation for OBI-902, a TROP2 Targeted Antibody-Drug Conjugate Therapy (ADC) in Advanced Solid Tumors

globenewswire

OBI Pharma Announces Phase 1/2 Study Initiation for OBI-902, a TROP2 Targeted Antibody-Drug Conjugate Therapy (ADC) in Advanced Solid Tumors – NEWSnet – News… as it used to be

More Press Releases

June 18, 2026

Xometry Expands Injection Molding Platform with a Wider Selection of Materials, On-Demand Expert Access and One-Click Reordering

June 18, 2026

BiomX Provides Update on Defense Technology Portfolio and Growth Strategy

June 18, 2026

OBM Appoints Marshall Long as Chief Revenue Officer

June 18, 2026

OBI Pharma Announces Phase 1/2 Study Initiation for OBI-902, a TROP2 Targeted Antibody-Drug Conjugate Therapy (ADC) in Advanced Solid Tumors

Xometry Expands Injection Molding Platform with a Wider Selection of Materials, On-Demand Expert Access and One-Click Reordering

BiomX Provides Update on Defense Technology Portfolio and Growth Strategy

OBM Appoints Marshall Long as Chief Revenue Officer

SK pharmteco Announces Strategic Collaboration with Orphan Therapeutics Accelerator for the Development and Manufacturing of Rare Disease Therapies